Company profile: NRx Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of clinical-stage therapeutics targeting central nervous system disorders and pulmonary diseases, with investigational products including NRX-101 for suicidal bipolar depression (Phase 3), chronic pain (Phase 2), and PTSD (Phase 2), and NRX-100 (IV ketamine) for severe bipolar depression post stabilization from a suicidal crisis (Phase 3).
Products and services
- NRX-101 for Suicidal Bipolar Depression: Phase 3 investigational drug engineered to treat bipolar depression in patients with acute suicidal ideation and behavior, for life-threatening central nervous system presentations
- NRX-100 (IV Ketamine) for Severe Bipolar Depression: Intravenous investigational treatment for severe bipolar depression in patients post stabilization from a suicidal crisis, advancing through Phase 3 clinical trials
- NRX-101 for PTSD: Phase 2 investigational therapy focusing on the NMDA and 5HT2A receptors for PTSD in patients with depression and suicidality
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NRx Pharmaceuticals
Aquapharm
HQ: United Kingdom
Website
- Description: Provider of drug discovery products based on the chemical diversity of marine micro-organisms, including novel pharmaceutical compounds and antibiotics for Gram negative and Gram positive infections, bio-manufactured nutraceuticals, personal care ingredients, and industrial biocatalysts. Maintains a proprietary library of over 7,000 marine micro-organisms and uses SeaRch™ technology to screen and induce production of biologically active compounds.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aquapharm company profile →
Helix BioMedix
HQ: United States
Website
- Description: Provider of skin health consumer products and bioactive peptide solutions for dermatological and personal care, including a proprietary peptide library with antimicrobial, anti-inflammatory and wound healing properties; SmartPeptides to enhance skin appearance; Oligopeptide-10 for acne; Palmitoyl Hexapeptide-14 and Hexapeptide-21 to stimulate collagen; and HB4208, a preclinical DNA Damage Response enzyme for Xeroderma Pigmentosum.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Helix BioMedix company profile →
Calixa Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical drug development focused on a novel cephalosporin to address multi-drug resistant organisms, targeting infections caused by resistant gram-negative bacteria, especially Pseudomonas aeruginosa.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calixa Therapeutics company profile →
Genticel
HQ: France
Website
- Description: Provider of therapeutic vaccines and innovative immunotherapies to treat virus infections and virus-induced diseases, with an initial focus on HPV and HPV-induced conditions, including prevention of cervical cancer in HPV-infected women.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genticel company profile →
NovaBay Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical eye care products, including Avenova Antimicrobial Lid and Lash Solution, Novawipes by Avenova, Avenova Lubricant Eye Drops, and Avenova Moist Heating Eye Compress, plus proprietary hypochlorous acid wound care solutions: NeutroPhase for cleansing and irrigating wounds (China) and PhaseOne for cleansing post-surgical wounds (US, professional use).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NovaBay Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NRx Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NRx Pharmaceuticals
2.2 - Growth funds investing in similar companies to NRx Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NRx Pharmaceuticals
4.2 - Public trading comparable groups for NRx Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →